Arbutus Biopharma Corporation Common Stock
ABUS Real Time Price USDRecent trades of ABUS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ABUS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
ABUS Revenue by Segment or Geography
New patents grants
-
Patent Title: Lipid nanoparticle formulations Mar. 18, 2025
-
Patent Title: Non-liposomal systems for nucleic acid delivery Oct. 29, 2024
-
Patent Title: Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same Sep. 10, 2024
-
Patent Title: Targeted compositions Jul. 23, 2024
-
Patent Title: Lipids and compositions for the delivery of therapeutics Jul. 23, 2024
-
Patent Title: Non-liposomal systems for nucleic acid delivery Jul. 16, 2024
-
Patent Title: Lipid compositions Jul. 02, 2024
-
Patent Title: Lipid formulations for delivery of therapeutic agents Jun. 25, 2024
-
Patent Title: Methods for ameliorating infusion reactions Feb. 20, 2024
-
Patent Title: Targeted nucleic acid conjugate compositions Feb. 13, 2024
-
Patent Title: Lipid formulations for delivery of therapeutic agents Oct. 17, 2023
-
Patent Title: Non-liposomal systems for nucleic acid delivery Aug. 08, 2023
-
Patent Title: Lipids and compositions for the delivery of therapeutics Aug. 01, 2023
-
Patent Title: Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same Jul. 18, 2023
-
Patent Title: Substituted tetrahydrocyclopenta[c]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same Jan. 31, 2023
-
Patent Title: Methods for preparing substituted pyridinone-containing tricyclic compounds Nov. 22, 2022
-
Patent Title: Lipid formulations for delivery of therapeutic agents Sep. 20, 2022
-
Patent Title: Targeted compositions Aug. 30, 2022
-
Patent Title: Lipid containing formulations Aug. 23, 2022
-
Patent Title: Trialkyl cationic lipids and methods of use thereof Jul. 26, 2022
-
Patent Title: Methods for ameliorating infusion reactions Jun. 07, 2022
-
Patent Title: Liposomal apparatus and manufacturing methods May. 03, 2022
-
Patent Title: Liposomal apparatus and manufacturing methods Apr. 12, 2022
-
Patent Title: Compositions and methods for delivering messenger rna Dec. 07, 2021
-
Patent Title: Lipid formulations for nucleic acid delivery Oct. 12, 2021
-
Patent Title: Substituted 2,3-dihydro-1h-indene analogs and methods using same Sep. 28, 2021
-
Patent Title: Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same Aug. 24, 2021
-
Patent Title: Lipids and compositions for the delivery of therapeutics Aug. 03, 2021
-
Patent Title: Substituted pyridinone-containing trycyclic compounds, and methods using same May. 25, 2021
-
Patent Title: Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same May. 11, 2021
-
Patent Title: Lipid compositions Mar. 23, 2021
-
Patent Title: Lipids and compositions for the delivery of therapeutics Nov. 17, 2020
-
Patent Title: Lipids and compositions for the delivery of therapeutics Nov. 03, 2020
-
Patent Title: Substituted pyridinone-containing trycyclic compounds, and methods using same Nov. 03, 2020
-
Patent Title: Trialkyl cationic lipids and methods of use thereof Feb. 18, 2020
-
Patent Title: Substituted 1-hydroxy-pyridin-2(1h)-ones, and methods of making and using same Feb. 04, 2020
-
Patent Title: Lipid compositions Oct. 29, 2019
-
Patent Title: Compositions and methods for silencing hepatitis b virus gene expression Sep. 17, 2019
-
Patent Title: Substituted 2-n-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same Jul. 23, 2019
-
Patent Title: Lipids and compositions for the delivery of therapeutics Nov. 06, 2018
-
Patent Title: Cyclic cationic lipids and methods of use Sep. 18, 2018
-
Patent Title: Methods for increasing efficacy of lipid formulated sirna Aug. 21, 2018
-
Patent Title: Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components Feb. 20, 2018
-
Patent Title: Targeting lipids Nov. 14, 2017
-
Patent Title: Lipids and compositions for the delivery of therapeutics Sep. 19, 2017
-
Patent Title: Lipids and compositions for the delivery of therapeutics Jul. 18, 2017
-
Patent Title: Lipid compositions Jul. 04, 2017
-
Patent Title: Compositions for nucleic acid delivery Jun. 27, 2017
-
Patent Title: Lipids and compositions for the delivery of therapeutics Jun. 20, 2017
-
Patent Title: Lipid containing formulations May. 30, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to ABUS
Recent picks made for ABUS stock on CNBC
ETFs with the largest estimated holdings in ABUS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ABUS stock a Buy, Sell, or Hold?
- What is the price target for $ABUS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ABUS stock?
- Who owns the most shares of $ABUS stock?
- What funds own $ABUS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ABUS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.